Miravista Diagnostics LLC
Indianapolis, IN
- UEI
- PQGQU8NUZ3T3
- CAGE
- 559E6
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- NAICS codes registered in SAM.gov
-
- 621511 Medical Laboratories Primary
- SAM.gov registration date
- Physical address
- 4705 Decatur Blvd, Indianapolis, IN 46241, USA
- Website
- miravistalabs.com
- Founded
- 2002
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Indy fungal testing services | Veterans Integrated Service Network 10 | $123,075 | |
| Mira vista | Veterans Integrated Service Network 9 | $92,475 | |
| Reference laboratory fungal testing services option to extend services funding task order | Veterans Integrated Service Network 10 | $21,021 | |
| Specialized fungal testing base year | Veterans Integrated Service Network 10 | $52,915 | |
| Fungal testing | Veterans Integrated Service Network 16 | $36,101 |
About Miravista Diagnostics LLC
Miravista Diagnostics LLC, an Indianapolis-based clinical laboratory specializing in fungal and microbiology diagnostic testing, operates exclusively as a prime contractor on federal reference laboratory testing awards with no set-asides, competing full-and-open based on proprietary patent ownership of fungal testing methodologies.
Miravista is a for-profit limited liability company and manufacturer of goods headquartered at 4705 Decatur Boulevard, Indianapolis, Indiana 46241. The vendor holds patents on specialized fungal diagnostic assays that justify sole-source procurements under FAR 13.106-1(b), enabling it to compete without small business set-asides across a portfolio dominated by the VA and clinical research agencies. Primary NAICS classification is 621511 (Medical Laboratories), with secondary work in 541711 (Research and Development in Biotechnology).
Miravista's customer base concentrates heavily on the Veterans Health Administration across multiple service networks. The top five funding entities account for 96% of combined potential value: VA Veterans Integrated Service Network 10 anchors the portfolio with 36 awards worth $3 million combined potential value; VA Veterans Integrated Service Network 9 holds 7 awards worth $1.5 million; VA Veterans Integrated Service Network 16 accounts for 12 awards worth $577 thousand; the NIH Clinical Center has awarded 5 contracts worth $314 thousand; and the CDC Pittsburgh office has placed 5 awards worth $102 thousand. Representative prime contracts include a $304.6 million indefinite delivery contract with VISN 10 (awarded November 2025, sole-source) for specialized fungal laboratory testing through November 2030; a $462,375 IDC with VISN 9 (awarded May 2025, sole-source) for reference laboratory fungal diagnostic testing through May 2030; and a $238,035 single-award IDC with VISN 10 (awarded May 2024) for esoteric fungal testing services. Delivery orders issued under these vehicles have ranged from $15 thousand to $199 thousand.
Miravista holds parent indefinite delivery contracts with VISN 10, VISN 9, and VISN 16; the vendor places task orders under five named IDCs with combined potential value of $1.6 million across 20 delivery orders. The source data reflects 95 total prime awards spanning 2007 to May 2026, with recent activity showing 7 awards in 2025 and 2 in 2026. Three awards face ultimate completion within the next twenty-four months with combined potential value of $74 thousand.
In addition to contract work, Miravista acts as prime recipient on a federal grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.866, Allergy, Immunology, and Transplantation Research) awarded August 2023 for development of a Coccidioides cytokine release assay, running through July 2027. The grant funds research on diagnostic tools for coccidioidomycosis, an endemic fungal disease with estimated annual U.S. incidence up to 350,000 cases. Miravista's technical position in fungal diagnostics rests on proprietary reference laboratory testing methodologies and patent protections that enable it to command full-and-open competition without relying on small business set-asides.
Quick answers
What is Miravista Diagnostics LLC's UEI?
Miravista Diagnostics LLC's Unique Entity ID (UEI) in SAM.gov is PQGQU8NUZ3T3.
What is Miravista Diagnostics LLC's CAGE code?
Miravista Diagnostics LLC's CAGE code is 559E6.
What is Miravista Diagnostics LLC's primary NAICS code?
Miravista Diagnostics LLC's primary NAICS code is 621511 (Medical Laboratories).
Where is Miravista Diagnostics LLC located?
Miravista Diagnostics LLC's physical address in SAM.gov is 4705 Decatur Blvd, Indianapolis, IN 46241, USA.
Is Miravista Diagnostics LLC registered in SAM.gov?
Yes. Miravista Diagnostics LLC's SAM.gov registration is active through July 22, 2027.
What is Miravista Diagnostics LLC's most recent federal award?
Miravista Diagnostics LLC's most recent federal contract award is Indy fungal testing services (36C25026N0694), from Veterans Integrated Service Network 10, on August 5, 2026.
On GovTribe
See Miravista Diagnostics LLC's full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors